The Clinical Research Infrastructure Initiative will benefit from additional funding from the UK government
The Clinical Research Infrastructure Initiative (CRII) will benefit from additional funding from the UK government and organizations like Arthritis Research UK, British Heart Foundation, the Wellcome Trust, and Cancer Research UK to advance clinical research in 23 key projects at centers across the UK.
Led by the UK's Medical Research Council, the CRII says it will invest more than 230 million pounds (around $368 million) on a range of medical and healthcare technologies for cancer and dementia and advanced diagnosis and treatment. For instance, Cardiff University will receive a total of 6.7 million pounds (8.47 million euros), including 3.4 million pounds (4.3 million euros) from the Welsh Government, for new ultra-high-field MRI technology to investigate the causes and treatments of dementia and other brain conditions, such as schizophrenia, Parkinson's disease, Huntington's disease, and multiple sclerosis.
Also, teams from the University of Leeds and the University of York are developing a new method that has the potential to increase the signal in an MRI scan by up to 100,000 times. The aim is to magnetically ‘label’ specific molecules so that they can be visualized as they pass through the body without changing their role. With this technique, it should be possible to label both drugs and substances that occur naturally in the body, making the method widely applicable. The technique could be applied to patients with heart disease, cancer and joint disease within five years and help speed up the development of new drugs.
Read the full release here.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.